Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT04229264
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 200 participants
- Sponsor
- Science Valley Research Institute
- Registry
-
NCT04229264
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Brazil
- Registry status
- Unknown status
Technical summary
Registry record NCT04229264. Randomized; no masking; primary purpose treatment. Start 2020-01-09 (actual); primary completion 2022-02-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.
- Acronym
- AGRIPPA
- Condition
- Critical Limb Ischemia
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- ASA
- Intervention (Drug)
- Clopidogrel 75mg
- Lead sponsor
- Science Valley Research Institute
- Collaborator
- Wyeth is now a wholly owned subsidiary of Pfizer
Record details
- Record id
cardio:ct-nct04229264- Content hash
61ee3d3a7aa9d2b791ea2db857fdef0a82e8b713664281de016723d68bef8c8e